Drugmaker Perrigo is to replace chief executive  Joseph Papa with president John Hendrickson (pictured) the company said on Monday. Papa will join rival  Valeant Pharmaceuticals International Inc. as CEO. (Phootgraph: Amir Cohen/Reuters)

Valeant Pharmaceuticals named Joseph Papa as its chief executive on Monday, the day after he resigned from the top spot at drugmaker Perrigo. The m(...)

Marks & Spencer: the retailer rose today, extending a rally from yesterday when its results beat forecasts

Global equity markets bounced, paced by a jump in oil prices today, but were still on track for a weekly decline. The Iseq rose as stocks on Wall St(...)

 Valeant Pharmaceuticals International: firm’s  US shares rose about 8 per cent in premarket trading. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals International said its lenders had agreed to give it an extra month to file its annual report, providing further reassurance t(...)

Allergan chief executive Brent Saunders gives an interview on the floor of the New York Stock Exchange as Allergan and Pfizer announce the end of their plan to merge. Photograph:  reuters/Brendan McDermid

Pfizer and Allergan have terminated their $160 billion merger in an abrupt end to the largest healthcare deal yet after the US government cracked down(...)

Both parties expected Addyi to hit $1 billion in net sales in the first full seven quarters following its introduction

Investors in Sprout, the female libido pill maker bought by Valeant Pharmaceuticals for $1 billion last year, have said the company has failed to suc(...)

Michael Pearson is to step down as  chairman of the board and chief executive officer of Valeant Pharmaceuticals International Inc.   The company has appointed activist investor William Ackman to its board. Photograph: Reuters

As recently as last summer, J Michael Pearson styled himself as a brash and bold executive with a new way of thriving in pharmaceuticals: buying othe(...)

The headquarters of Valeant Pharmaceuticals in Laval, Quebec. Photograph: Christinne Muschi/ Reuters

Embattled pharmaceutical company Valeant said its chief executive Michael Pearson will step down as it added Bill Ackman, one of its largest investors(...)

 Valeant Pharmaceuticals International  in Quebec: it has  incurred a heavy debt load because of a string of acquisitions. Photograph:  Christinne Muschi/Reuters

Valeant Pharmaceuticals International has cut its 2016 revenue forecast by about 12 percent and said a delay in filing its annual report could mean a (...)

Valeant Pharmaceuticals plunged as much as 42 per cent to the lowest since 2011 after cutting its sales forecast. Photograph: Christinne Muschi/Reuters

Global stocks dropped on Tuesday as the biggest two-day slide for commodity prices in a month reminded investors of the financial-market turmoil that (...)

Michael “Mike” Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International, said he was “comfortable” with the company’s liquidity and expected Valeant to meet obligations. (Photograph: Scott Eells/Bloomberg)

Valeant Pharmaceuticals cut its 2016 revenue forecast by about 12 per cent on Tuesday and said a delay in filing its annual report could pose a debt (...)